Andere Sprachen Regencell Bioscience Holdings Limited

Aktien

A3CY32

KYG7487R1002

RGC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
5.33 ^USD	-17.87%		+14.62%	-49.24%

2023	Regencell Bioscience Holdings Limited berichtet über die Ergebnisse für das am 30. Juni 2023 zu Ende gegangene Geschäftsjahr	CI
2023	Regencell Bioscience Holdings Limited berichtet über die Ergebnisse für das am 31. Dezember 2022 endende Halbjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Regencell Bioscience : Resignation of Yi-Chung Chao as Director - Form 6-K	02.01.
Regencell Bioscience : Form of Letter of Lock-up Undertaking - Form 6-K	15.12.
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	27.10.23
Regencell Bioscience : Announces First Half 2023 Management Financial Results - Form 6-K	15.06.23
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	15.06.23
Regencell Bioscience : Changes in Registrant’s Certifying Accountant - Form 6-K	17.03.23
Regencell Bioscience : Appointment of Chief Business Officer - Form 6-K	28.02.23
Regencell Bioscience Holdings Limited Promotes Yat-Pui Au from Senior Vice President to Chief Business Officer	28.02.23
Regencell Bioscience : Letter of Lock-Up Undertaking - Form 6-K	04.01.23
Regencell Bioscience : Resignation of Chief Medical Officer - Form 6-K	22.12.22
Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022	22.12.22
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31.10.22
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial	12.09.22
Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial	12.09.22
Regencell Bioscience : Announces First Half 2022 Management Financial Results - Form 6-K	02.06.22
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2021	02.06.22
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period	18.05.22
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period	18.05.22
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO	16.05.22
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO	16.05.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Regencell Bioscience Holdings Limited

Aktien

A3CY32

KYG7487R1002

RGC

Andere Sprachen

Filter